Exelixis | EXEL - Koszty Sprzedaży





Koszty Sprzedaży Zmiana Data
Acadia Pharmaceuticals USD 24.79M 1.43M 2026-03
Agios Pharmaceuticals USD 1.32M 560K 2026-03
Akebia Therapeutics USD 10.34M 441K 2025-12
Amgen USD 1.6B 187M 2026-03
AstraZeneca USD -204M 3.48B 2026-03
Bayer EUR 5.23B 731M 2026-03
BioMarin Pharmaceutical USD 199.48M 37.93M 2026-03
Bristol-Myers Squibb USD 3.86B 1.07B 2026-03
Cytokinetics USD 160K 104.24M 2026-03
Eisai JPY 52.02B 931M 2026-03
Eli Lilly USD 3.58B 205M 2026-03
Esperion Therapeutics USD 27.85M 13.43M 2025-12
Exelixis USD 19.95M 6.53M 2026-03
Genmab DKK 81M 23M 2025-12
Glaxosmithkline GBP 3.47B 461.37M 2025-12
Incyte USD 104.5M 16.68M 2026-03
Ionis Pharmaceuticals USD 3M 5M 2026-03
MacroGenics USD 10.12M 34.18M 2025-12
Merck USD 2.94B 380M 2026-03
Moderna USD 955M 503M 2026-03
Nektar Therapeutics USD 4.43M 5.3M 2024-09
Neurocrine Biosciences USD 13.8M 3.8M 2026-03
Novartis USD 3.46B 83M 2026-03
Pfizer USD 4.59B 1.7B 2026-03
Puma Biotechnology USD 29.1M 18.44M 2024-09
Sanofi EUR 3.76B 344M 2025-12
Takeda JPY 560.54B 159.39B 2026-03
Ultragenyx Pharmaceutical USD 30M 1000K 2026-03
Xencor USD 61.66M 50.95M 2025-06